Pharmacologic and genetic strategies to enhance cell therapy for cardiac regeneration

Journal of Molecular and Cellular Cardiology

Volumn 51, Issue 4, 2011, Pages 619-625

  Kanashiro Takeuchi, Rosemeire M ^a   Schulman, Ivonne Hernandez ^a,b   Hare, Joshua M ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b Miami Veterans Affairs Healthcare System   (United States)

Author keywords

Cardiogenesis; Chemokines; Growth factors; Regeneration; Small molecules; Stem cell

Indexed keywords

ASCORBIC ACID; AZACITIDINE; CHEMOKINE RECEPTOR CCR1; ERYTHROPOIETIN; FIBROBLAST GROWTH FACTOR 2; GLYCOGEN SYNTHASE KINASE 3BETA; GRANULOCYTE COLONY STIMULATING FACTOR; GROWTH FACTOR; GROWTH HORMONE RELEASING FACTOR; HETEROTRIMERIC GUANINE NUCLEOTIDE BINDING PROTEIN INHIBITOR; HYDRAZONE DERIVATIVE; KRUPPEL LIKE FACTOR 4; MYC PROTEIN; NERVE GROWTH FACTOR; NEU DIFFERENTIATION FACTOR; OCTAMER TRANSCRIPTION FACTOR 4; PLATELET DERIVED GROWTH FACTOR AB; PROTEIN INHIBITOR; PYRIVINIUM; RESVERATROL; SCATTER FACTOR; SOMATOMEDIN C; STEM CELL FACTOR; STROMAL CELL DERIVED FACTOR 1ALPHA; SULFONYL HYDRAZONE; TRANSCRIPTION FACTOR SOX2; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULOTROPIN; WNT PROTEIN INHIBITOR; XAV 939;

ADULT STEM CELL; CARDIAC REGENERATION; CELL DIFFERENTIATION; CELL HOMING; CELL LINEAGE; CELL PROLIFERATION; CELL REGENERATION; CELL SURVIVAL; CELL THERAPY; CLINICAL RESEARCH; GENETIC ENGINEERING; HEART FAILURE; HEART INFARCTION; HEART INJURY; HUMAN; MULTIPOTENT STEM CELL; NONHUMAN; NUCLEAR REPROGRAMMING; PLURIPOTENT STEM CELL; PREVALENCE; PRIORITY JOURNAL; REGENERATIVE MEDICINE; REVIEW; SINGLE DRUG DOSE; TISSUE REGENERATION;

ANIMALS; CLINICAL TRIALS AS TOPIC; ERYTHROPOIETIN; GENE THERAPY; GENETIC ENGINEERING; GRANULOCYTE COLONY-STIMULATING FACTOR; HEART; HEART FAILURE; HUMANS; REGENERATION; STEM CELL TRANSPLANTATION; STEM CELLS;

IPS;

EID: 80052799122     PISSN: 00222828     EISSN: 10958584     Source Type: Journal    
DOI: 10.1016/j.yjmcc.2011.05.015     Document Type: Review

References (102)

1. Lloyd-Jones D., Adams R.J., Brown T.M., Carnethon M., Dai S., de Simone G., et al. Heart disease and stroke statistics-2010 update: a report from the American Heart Association. Circulation 2010, 121:e46-e215.
2. Anversa P., Kajstura J., Leri A., Bolli R. Life and death of cardiac stem cells: a paradigm shift in cardiac biology. Circulation 2006, 113:1451-1463.
3. Filipczyk A.A., Passier R., Rochat A., Mummery C.L. Regulation of cardiomyocyte differentiation of embryonic stem cells by extracellular signalling. Cell Mol Life Sci 2007, 64:704-718.
4. Segers V.F., Lee R.T. Stem-cell therapy for cardiac disease. Nature 2008, 451:937-942.
5. Takahashi K., Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 2006, 126:663-676.
6. Takahashi K., Tanabe K., Ohnuki M., Narita M., Ichisaka T., Tomoda K., et al. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 2007, 131:861-872.
7. Yu J., Vodyanik M.A., Smuga-Otto K., Antosiewicz-Bourget J., Frane J.L., Tian S., et al. Induced pluripotent stem cell lines derived from human somatic cells. Science 2007, 318:1917-1920.
8. Nakagawa M., Koyanagi M., Tanabe K., Takahashi K., Ichisaka T., Aoi T., et al. Generation of induced pluripotent stem cells without Myc from mouse and human fibroblasts. Nat Biotechnol 2008, 26:101-106.
9. Martinez-Fernandez A., Nelson T.J., Yamada S., Reyes S., Alekseev A.E., Perez-Terzic C., et al. iPS programmed without c-MYC yield proficient cardiogenesis for functional heart chimerism. Circ Res 2009, 105:648-656.
10. Martinez-Fernandez A., Nelson T.J., Ikeda Y., Terzic A. c-MYC independent nuclear reprogramming favors cardiogenic potential of induced pluripotent stem cells. J Cardiovasc Transl Res 2010, 3:13-23.
11. Huangfu D., Maehr R., Guo W., Eijkelenboom A., Snitow M., Chen A.E., et al. Induction of pluripotent stem cells by defined factors is greatly improved by small-molecule compounds. Nat Biotechnol 2008, 26:795-797.
12. Shi Y., Do J.T., Desponts C., Hahm H.S., Scholer H.R., Ding S. A combined chemical and genetic approach for the generation of induced pluripotent stem cells. Cell Stem Cell 2008, 2:525-528.
13. Maherali N., Hochedlinger K. Tgfbeta signal inhibition cooperates in the induction of iPSCs and replaces Sox2 and cMyc. Curr Biol 2009, 19:1718-1723.
14. Bearzi C., Rota M., Hosoda T., Tillmanns J., Nascimbene A., De A.A., et al. Human cardiac stem cells. Proc Natl Acad Sci USA 2007, 104:14068-14073.
15. Beltrami A.P., Barlucchi L., Torella D., Baker M., Limana F., Chimenti S., et al. Adult cardiac stem cells are multipotent and support myocardial regeneration. Cell 2003, 114:763-776.
16. Zaruba M.M., Soonpaa M., Reuter S., Field L.J. Cardiomyogenic potential of C-kit(+)-expressing cells derived from neonatal and adult mouse hearts. Circulation 2010, 121:1992-2000.
17. Oh H., Bradfute S.B., Gallardo T.D., Nakamura T., Gaussin V., Mishina Y., et al. Cardiac progenitor cells from adult myocardium: homing, differentiation, and fusion after infarction. Proc Natl Acad Sci USA 2003, 100:12313-12318.
18. Linke A., Muller P., Nurzynska D., Casarsa C., Torella D., Nascimbene A., et al. Stem cells in the dog heart are self-renewing, clonogenic, and multipotent and regenerate infarcted myocardium, improving cardiac function. Proc Natl Acad Sci USA 2005, 102:8966-8971.
19. Suzuki G., Iyer V., Cimato T., Canty J.M. Pravastatin improves function in hibernating myocardium by mobilizing CD133+ and cKit+bone marrow progenitor cells and promoting myocytes to reenter the growth phase of the cardiac cell cycle. Circ Res 2009, 104:255-264.
20. Fischer K.M., Cottage C.T., Wu W., Din S., Gude N.A., Avitabile D., et al. Enhancement of myocardial regeneration through genetic engineering of cardiac progenitor cells expressing Pim-1 kinase. Circulation 2009, 120:2077-2087.
21. Gnecchi M., Zhang Z., Ni A., Dzau V.J. Paracrine mechanisms in adult stem cell signaling and therapy. Circ Res 2008, 103:1204-1219.
22. Korf-Klingebiel M., Kempf T., Sauer T., Brinkmann E., Fischer P., Meyer G.P., et al. Bone marrow cells are a rich source of growth factors and cytokines: implications for cell therapy trials after myocardial infarction. Eur Heart J 2008, 29:2851-2858.
23. Askari A.T., Unzek S., Popovic Z.B., Goldman C.K., Forudi F., Kiedrowski M., et al. Effect of stromal-cell-derived factor 1 on stem-cell homing and tissue regeneration in ischaemic cardiomyopathy. Lancet 2003, 362:697-703.
24. Zhang G., Nakamura Y., Wang X., Hu Q., Suggs L.J., Zhang J. Controlled release of stromal cell-derived factor-1 alpha in situ increases c-kit+cell homing to the infarcted heart. Tissue Eng 2007, 13:2063-2071.
25. Yamaguchi J., Kusano K.F., Masuo O., Kawamoto A., Silver M., Murasawa S., et al. Stromal cell-derived factor-1 effects on ex vivo expanded endothelial progenitor cell recruitment for ischemic neovascularization. Circulation 2003, 107:1322-1328.
26. Sasaki T., Fukazawa R., Ogawa S., Kanno S., Nitta T., Ochi M., et al. Stromal cell-derived factor-1alpha improves infarcted heart function through angiogenesis in mice. Pediatr Int 2007, 49:966-971.
27. Saxena A., Fish J.E., White M.D., Yu S., Smyth J.W., Shaw R.M., et al. Stromal cell-derived factor-1alpha is cardioprotective after myocardial infarction. Circulation 2008, 117:2224-2231.
28. Schenk S., Mal N., Finan A., Zhang M., Kiedrowski M., Popovic Z., et al. Monocyte chemotactic protein-3 is a myocardial mesenchymal stem cell homing factor. Stem Cells 2007, 25:245-251.
29. Kocher A.A., Schuster M.D., Bonaros N., Lietz K., Xiang G., Martens T.P., et al. Myocardial homing and neovascularization by human bone marrow angioblasts is regulated by IL-8/Gro CXC chemokines. J Mol Cell Cardiol 2006, 40:455-464.
30. Nakamura T., Mizuno S., Matsumoto K., Sawa Y., Matsuda H., Nakamura T. Myocardial protection from ischemia/reperfusion injury by endogenous and exogenous HGF. J Clin Invest 2000, 106:1511-1519.
31. Wang Y., Ahmad N., Wani M.A., Ashraf M. Hepatocyte growth factor prevents ventricular remodeling and dysfunction in mice via Akt pathway and angiogenesis. J Mol Cell Cardiol 2004, 37:1041-1052.
32. Rota M., Padin-Iruegas M.E., Misao Y., De A.A., Maestroni S., Ferreira-Martins J., et al. Local activation or implantation of cardiac progenitor cells rescues scarred infarcted myocardium improving cardiac function. Circ Res 2008, 103:107-116.
33. Rosenblatt-Velin N., Lepore M.G., Cartoni C., Beermann F., Pedrazzini T. FGF-2 controls the differentiation of resident cardiac precursors into functional cardiomyocytes. J Clin Invest 2005, 115:1724-1733.
34. Torella D., Rota M., Nurzynska D., Musso E., Monsen A., Shiraishi I., et al. Cardiac stem cell and myocyte aging, heart failure, and insulin-like growth factor-1 overexpression. Circ Res 2004, 94:514-524.
35. Padin-Iruegas M.E., Misao Y., Davis M.E., Segers V.F., Esposito G., Tokunou T., et al. Cardiac progenitor cells and biotinylated insulin-like growth factor-1 nanofibers improve endogenous and exogenous myocardial regeneration after infarction. Circulation 2009, 120:876-887.
36. Urbanek K., Rota M., Cascapera S., Bearzi C., Nascimbene A., De A.A., et al. Cardiac stem cells possess growth factor-receptor systems that after activation regenerate the infarcted myocardium, improving ventricular function and long-term survival. Circ Res 2005, 97:663-673.
37. Cheng M., Zhou J., Wu M., Boriboun C., Thorne T., Liu T., et al. CXCR4-mediated bone marrow progenitor cell maintenance and mobilization are modulated by c-kit activity. Circ Res 2010, 107:1083-1093.
38. Tang Y.L., Zhu W., Cheng M., Chen L., Zhang J., Sun T., et al. Hypoxic preconditioning enhances the benefit of cardiac progenitor cell therapy for treatment of myocardial infarction by inducing CXCR4 expression. Circ Res 2009, 104:1209-1216.
39. Tang J.M., Wang J.N., Zhang L., Zheng F., Yang J.Y., Kong X., et al. VEGF/SDF-1 promotes cardiac stem cell mobilization and myocardial repair in the infarcted heart. Cardiovasc Res 2011, 91:402-411.
40. Zisa D., Shabbir A., Mastri M., Suzuki G., Lee T. Intramuscular VEGF repairs the failing heart: role of host-derived growth factors and mobilization of progenitor cells. Am J Physiol Regul Integr Comp Physiol 2009, 297:R1503-R1515.
41. Lehrke S., Mazhari R., Durand D.J., Zheng M., Bedja D., Zimmet J.M., et al. Aging impairs the beneficial effect of granulocyte colony-stimulating factor and stem cell factor on post-myocardial infarction remodeling. Circ Res 2006, 99:553-560.
42. Xiang F.L., Lu X., Hammoud L., Zhu P., Chidiac P., Robbins J., et al. Cardiomyocyte-specific overexpression of human stem cell factor improves cardiac function and survival after myocardial infarction in mice. Circulation 2009, 120:1065-1074. 9.
43. Kanashiro-Takeuchi R.M., Tziomalos K., Takeuchi L.M., Treuer A.V., Lamirault G., Dulce R., et al. Cardioprotective effects of growth hormone-releasing hormone agonist after myocardial infarction. Proc Natl Acad Sci USA 2010, 107:2604-2609.
44. Meloni M., Caporali A., Graiani G., Lagrasta C., Katare R., Van L.S., et al. Nerve growth factor promotes cardiac repair following myocardial infarction. Circ Res 2010, 106:1275-1284.
45. Mangi A.A., Noiseux N., Kong D., He H., Rezvani M., Ingwall J.S., et al. Mesenchymal stem cells modified with Akt prevent remodeling and restore performance of infarcted hearts. Nat Med 2003, 9:1195-1201.
46. Muraski J.A., Rota M., Misao Y., Fransioli J., Cottage C., Gude N., et al. Pim-1 regulates cardiomyocyte survival downstream of Akt. Nat Med 2007, 13:1467-1475.
47. Cottage C.T., Bailey B., Fischer K.M., Avitable D., Collins B., Tuck S., et al. Cardiac progenitor cell cycling stimulated by pim-1 kinase. Circ Res 2010, 106:891-901.
48. Iwakura A., Shastry S., Luedemann C., Hamada H., Kawamoto A., Kishore R., et al. Estradiol enhances recovery after myocardial infarction by augmenting incorporation of bone marrow-derived endothelial progenitor cells into sites of ischemia-induced neovascularization via endothelial nitric oxide synthase-mediated activation of matrix metalloproteinase-9. Circulation 2006, 113:1605-1614.
49. Walter D.H., Zeiher A.M., Dimmeler S. Effects of statins on endothelium and their contribution to neovascularization by mobilization of endothelial progenitor cells. Coron Artery Dis 2004, 15:235-242.
50. Aicher A., Heeschen C., Mildner-Rihm C., Urbich C., Ihling C., Technau-Ihling K., et al. Essential role of endothelial nitric oxide synthase for mobilization of stem and progenitor cells. Nat Med 2003, 9:1370-1376.
51. Wu Y., Ip J.E., Huang J., Zhang L., Matsushita K., Liew C.C., et al. Essential role of ICAM-1/CD18 in mediating EPC recruitment, angiogenesis, and repair to the infarcted myocardium. Circ Res 2006, 99:315-322.
52. van der Meer P., Lipsic E., Henning R.H., Boddeus K., van der Velden J., Voors A.A., et al. Erythropoietin induces neovascularization and improves cardiac function in rats with heart failure after myocardial infarction. J Am Coll Cardiol 2005, 46:125-133.
53. Prunier F., Pfister O., Hadri L., Liang L., del M.F., Liao R., et al. Delayed erythropoietin therapy reduces post-MI cardiac remodeling only at a dose that mobilizes endothelial progenitor cells. Am J Physiol Heart Circ Physiol 2007, 292:H522-H529.
54. Kanashiro-Takeuchi RM, Takeuchi L, Hatzistergos C, Quevedo H, Selem S, Treuer AV et al. Effects of combination of proliferative agents and erythropoietin on left ventricular remodeling post myocardial infarction. There is no update. Manuscript was accepted on Feb 21, 2011.
55. Hare J.M., Traverse J.H., Henry T.D., Dib N., Strumpf R.K., Schulman S.P., et al. A randomized, double-blind, placebo-controlled, dose-escalation study of intravenous adult human mesenchymal stem cells (prochymal) after acute myocardial infarction. J Am Coll Cardiol 2009, 54:2277-2286.
56. Williams A.R., Trachtenberg B., Velazquez D.L., McNiece I., Altman P., Rouy D., et al. Intramyocardial stem cell injection in patients with ischemic cardiomyopathy: functional recovery and reverse remodeling. Circ Res 2011, 108:792-796.
57. Herrmann J.L., Markel T.A., Abarbanell A.M., Weil B.R., Wang M., Wang Y., et al. Proinflammatory stem cell signaling in cardiac ischemia. Antioxid Redox Signal 2009, 11:1883-1896.
58. Hahn J.Y., Cho H.J., Kang H.J., Kim T.S., Kim M.H., Chung J.H., et al. Pre-treatment of mesenchymal stem cells with a combination of growth factors enhances gap junction formation, cytoprotective effect on cardiomyocytes, and therapeutic efficacy for myocardial infarction. J Am Coll Cardiol 2008, 51:933-943.
59. Hausenloy D.J., Yellon D.M. Cardioprotective growth factors. Cardiovasc Res 2009, 83:179-194.
60. Behfar A., Yamada S., Crespo-Diaz R., Nesbitt J.J., Rowe L.A., Perez-Terzic C., et al. Guided cardiopoiesis enhances therapeutic benefit of bone marrow human mesenchymal stem cells in chronic myocardial infarction. J Am Coll Cardiol 2010, 56:721-734.
61. Bartunek J., Croissant J.D., Wijns W., Gofflot S., de L.A., Vanderheyden M., et al. Pretreatment of adult bone marrow mesenchymal stem cells with cardiomyogenic growth factors and repair of the chronically infarcted myocardium. Am J Physiol Heart Circ Physiol 2007, 292:H1095-H1104.
62. Behfar A., Zingman L.V., Hodgson D.M., Rauzier J.M., Kane G.C., Terzic A., et al. Stem cell differentiation requires a paracrine pathway in the heart. FASEB J 2002, 16:1558-1566.
63. Xaymardan M., Tang L., Zagreda L., Pallante B., Zheng J., Chazen J.L., et al. Platelet-derived growth factor-AB promotes the generation of adult bone marrow-derived cardiac myocytes. Circ Res 2004, 94:E39-E45.
64. Hirotani S., Zhai P., Tomita H., Galeotti J., Marquez J.P., Gao S., et al. Inhibition of glycogen synthase kinase 3beta during heart failure is protective. Circ Res 2007, 101:1164-1174.
65. Cho J., Rameshwar P., Sadoshima J. Distinct roles of glycogen synthase kinase (GSK)-3alpha and GSK-3beta in mediating cardiomyocyte differentiation in murine bone marrow-derived mesenchymal stem cells. J Biol Chem 2009, 284:36647-36658.
66. Jin Y.H., Kim H., Oh M., Ki H., Kim K. Regulation of Notch1/NICD and Hes1 expressions by GSK-3alpha/beta. Mol Cells 2009, 27:15-19.
67. Riobo N.A., Lu K., Ai X., Haines G.M., Emerson C.P. Phosphoinositide 3-kinase and Akt are essential for Sonic Hedgehog signaling. Proc Natl Acad Sci USA 2006, 103:4505-4510.
68. Cho J., Zhai P., Maejima Y., Sadoshima J. Myocardial injection with GSK- 3beta-overexpressing bone marrow-derived mesenchymal stem cells attenuates cardiac dysfunction after myocardial infarction. Circ Res 2011, 108:478-489.
69. Huang J., Zhang Z., Guo J., Ni A., Deb A., Zhang L., et al. Genetic modification of mesenchymal stem cells overexpressing CCR1 increases cell viability, migration, engraftment, and capillary density in the injured myocardium. Circ Res 2010, 106:1753-1762.
70. Zhu W.Z., Xie Y., Moyes K.W., Gold J.D., Askari B., Laflamme M.A. Neuregulin/ErbB signaling regulates cardiac subtype specification in differentiating human embryonic stem cells. Circ Res 2010, 107:776-786.
71. Koyanagi M., Iwasaki M., Rupp S., Tedesco F.S., Yoon C.H., Boeckel J.N., et al. Sox2 transduction enhances cardiovascular repair capacity of blood-derived mesoangioblasts. Circ Res 2010, 106:1290-1302.
72. Ieda M., Fu J.D., Delgado-Olguin P., Vedantham V., Hayashi Y., Bruneau B.G., et al. Direct reprogramming of fibroblasts into functional cardiomyocytes by defined factors. Cell 2010, 142:375-386.
73. Penn M.S., Mangi A.A. Genetic enhancement of stem cell engraftment, survival, and efficacy. Circ Res 2008, 102:1471-1482.
74. Gupta R., Tongers J., Losordo D.W. Human studies of angiogenic gene therapy. Circ Res 2009, 105:724-736.
75. Mushtaq M., Oskouei B.N., Hare J.M. Cell therapy for heart disease: to genetically modify or not, that is the question. Circ Res 2011, 108:398-401.
76. Sadek H., Hannack B., Choe E., Wang J., Latif S., Garry M.G., et al. Cardiogenic small molecules that enhance myocardial repair by stem cells. Proc Natl Acad Sci USA 2008, 105:6063-6068.
77. Quattrocelli M., Palazzolo G., Agnolin I., Martino S., Bouche M., Anastasia L., et al. Synthetic sulfonyl-hydrazone-1 positively regulates cardiomyogenic microRNA expression and cardiomyocyte differentiation of induced pluripotent stem cells. J Cell Biochem 2011, 112:2006-2014.
78. Takahashi T., Lord B., Schulze P.C., Fryer R.M., Sarang S.S., Gullans S.R., et al. Ascorbic acid enhances differentiation of embryonic stem cells into cardiac myocytes. Circulation 2003, 107:1912-1916.
79. Wang H., Hao J., Hong C.C. Cardiac induction of embryonic stem cells by a small molecule inhibitor of Wnt/beta-catenin signaling. ACS Chem Biol 2011, 6:192-197.
80. Saraswati S., Alfaro M.P., Thorne C.A., Atkinson J., Lee E., Young P.P. Pyrvinium, a potent small molecule Wnt inhibitor, promotes wound repair and post-MI cardiac remodeling. PLoS One 2010, 5:e15521.
81. Kamal F.A., Smrcka A.V., Blaxall B.C. Taking the heart failure battle inside the cell: small molecule targeting of Gβγ subunits. J Mol Cell Cardiol 2011, 51(4):462-467.
82. Ventura C., Cantoni S., Bianchi F., Lionetti V., Cavallini C., Scarlata I., et al. Hyaluronan mixed esters of butyric and retinoic acid drive cardiac and endothelial fate in term placenta human mesenchymal stem cells and enhance cardiac repair in infarcted rat hearts. J Biol Chem 2007, 282:14243-14252.
83. Simioniuc A., Campan M., Lionetti V., Marinelli M., Aquaro G.D., Cavallini C., et al. Placental stem cells pre-treated with a hyaluronan mixed ester of butyric and retinoic acid to cure infarcted pig hearts: a multimodal study. Cardiovasc Res 2011, 90:546-556.
84. Makino S., Fukuda K., Miyoshi S., Konishi F., Kodama H., Pan J., et al. Cardiomyocytes can be generated from marrow stromal cells in vitro. J Clin Invest 1999, 103:697-705.
85. Ye N.S., Chen J., Luo G.A., Zhang R.L., Zhao Y.F., Wang Y.M. Proteomic profiling of rat bone marrow mesenchymal stem cells induced by 5-azacytidine. Stem Cells Dev 2006, 15:665-676.
86. Burlacu A., Rosca A.M., Maniu H., Titorencu I., Dragan E., Jinga V., et al. Promoting effect of 5-azacytidine on the myogenic differentiation of bone marrow stromal cells. Eur J Cell Biol 2008, 87:173-184.
87. Yoon J., Min B.G., Kim Y.H., Shim W.J., Ro Y.M., Lim D.S. Differentiation, engraftment and functional effects of pre-treated mesenchymal stem cells in a rat myocardial infarct model. Acta Cardiol 2005, 60:277-284.
88. Huang P.H., Chen Y.H., Tsai H.Y., Chen J.S., Wu T.C., Lin F.Y., et al. Intake of red wine increases the number and functional capacity of circulating endothelial progenitor cells by enhancing nitric oxide bioavailability. Arterioscler Thromb Vasc Biol 2010, 30:869-877.
89. Xia L., Wang X.X., Hu X.S., Guo X.G., Shang Y.P., Chen H.J., et al. Resveratrol reduces endothelial progenitor cells senescence through augmentation of telomerase activity by Akt-dependent mechanisms. Br J Pharmacol 2008, 155:387-394.
90. Gorbunov N, Petrovski G, Gurusamy N, Ray D, Kim DH, Das DK. Regeneration of infarcted myocardium with resveratrol-modified cardiac stem cells. J Cell Mol Med in press, http://doi:10.1111/j.1582-4934.2011.01281.x.
91. Kang H.J., Kim H.S., Zhang S.Y., Park K.W., Cho H.J., Koo B.K., et al. Effects of intracoronary infusion of peripheral blood stem-cells mobilised with granulocyte-colony stimulating factor on left ventricular systolic function and restenosis after coronary stenting in myocardial infarction: the MAGIC cell randomised clinical trial. Lancet 2004, 363:751-756.
92. Ince H., Petzsch M., Kleine H.D., Schmidt H., Rehders T., Korber T., et al. Preservation from left ventricular remodeling by front-integrated revascularization and stem cell liberation in evolving acute myocardial infarction by use of granulocyte-colony-stimulating factor (FIRSTLINE-AMI). Circulation 2005, 112:3097-3106.
93. Ripa R.S., Jorgensen E., Wang Y., Thune J.J., Nilsson J.C., Sondergaard L., et al. Stem cell mobilization induced by subcutaneous granulocyte-colony stimulating factor to improve cardiac regeneration after acute ST-elevation myocardial infarction: result of the double-blind, randomized, placebo-controlled stem cells in myocardial infarction (STEMMI) trial. Circulation 2006, 113:1983-1992.
94. Ripa R.S., Haack-Sorensen M., Wang Y., Jorgensen E., Mortensen S., Bindslev L., et al. Bone marrow derived mesenchymal cell mobilization by granulocyte-colony stimulating factor after acute myocardial infarction: results from the Stem Cells in Myocardial Infarction (STEMMI) trial. Circulation 2007, 116:I24-I30.
95. Zohlnhofer D., Ott I., Mehilli J., Schomig K., Michalk F., Ibrahim T., et al. Stem cell mobilization by granulocyte colony-stimulating factor in patients with acute myocardial infarction: a randomized controlled trial. JAMA 2006, 295:1003-1010.
96. Lipsic E., van der Meer P., Voors A.A., Westenbrink B.D., van den Heuvel A.F., de Boer H.C., et al. A single bolus of a long-acting erythropoietin analogue darbepoetin alfa in patients with acute myocardial infarction: a randomized feasibility and safety study. Cardiovasc Drugs Ther 2006, 20:135-141.
97. Voors A.A., Belonje A.M., Zijlstra F., Hillege H.L., Anker S.D., Slart R.H., et al. A single dose of erythropoietin in ST-elevation myocardial infarction. Eur Heart J 2010, 31:2593-2600.
98. Ott I., Schulz S., Mehilli J., Fichtner S., Hadamitzky M., Hoppe K., et al. Erythropoietin in patients with acute ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: a randomized, double-blind trial. Circ Cardiovasc Interv 2010, 3:408-413.
99. Melloni C., Rao S.V., Povsic T.J., Melton L., Kim R.J., Kilaru R., et al. Design and rationale of the Reduction of Infarct Expansion and Ventricular Remodeling with Erythropoietin after Large Myocardial Infarction (REVEAL) trial. Am Heart J 2010, 160:795-803.
100. Andreotti F., Agati L., Conti E., Santucci E., Rio T., Tarantino F., et al. Update on phase II studies of erythropoietin in acute myocardial infarction. Rationale and design of Exogenous erythroPoietin in Acute Myocardial Infarction: New Outlook aNd Dose Association Study (EPAMINONDAS). J Thromb Thrombolysis 2009, 28:489-495.
101. Jaski B.E., Jessup M.L., Mancini D.M., Cappola T.P., Pauly D.F., Greenberg B., et al. Calcium upregulation by percutaneous administration of gene therapy in cardiac disease (CUPID Trial), a first-in-human phase 1/2 clinical trial. J Card Fail 2009, 15:171-181.
102. Lipskaia L., Chemaly E.R., Hadri L., Lompre A.M., Hajjar R.J. Sarcoplasmic reticulum Ca(2+) ATPase as a therapeutic target for heart failure. Expert Opin Biol Ther 2010, 10:29-41.